Skip to main content

Michael Vicari

OncoCyte has appointed Michael Vicari to a newly created position of vice president of sales, in which he will report directly to president and CEO William Annett. In his new role, Vicari will be responsible for the development and successful implementation of domestic and international sales strategies for OncoCyte, with an initial focus on the expected fourth quarter US launch of the firm's liquid biopsy lung cancer test DetermaVu.

Vicari comes with 35 years of successful sales and marketing leadership within the healthcare industry, including the launch of several important diagnostic products, OncoCyte said. He previously worked with Eurofins Scientific as VP of sales & marketing for the company's clinical diagnostics business. Prior to Eurofins, he was VP of sales for Sequenom, for Monogram Biosciences, and served in senior commercial leadership roles at Genentech, Corixa Oncology, and MedImmune.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.